Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

Cancer Cell

Volumn 29, Issue 6, 2016, Pages 820-831

  Dahan, Rony ^a   Barnhart, Bryan C ^b   Li, Fubin ^a   Yamniuk, Aaron P ^b   Korman, Alan J ^b   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CP 870893; FC RECEPTOR IIB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; FC RECEPTOR; FC RECEPTOR IIA; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TUMOR IMMUNITY; AGONISTS; ANIMAL; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD40; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976493966     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.05.001     Document Type: Article

References (40)

1. Allen, M.J., Guo, A., Martinez, T., Han, M., Flynn, G.C., Wypych, J., Liu, Y.D., Shen, W.D., Dillon, T.M., Vezina, C., Balland, A., Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis. Biochemistry 48 (2009), 3755–3766.
2. Bajor, D.L., Xu, X., Torigian, D.A., Mick, R., Garcia, L.R., Richman, L.P., Desmarais, C., Nathanson, K.L., Schuchter, L.M., Kalos, M., Vonderheide, R.H., Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol. Res. 2 (2014), 1051–1058.
3. Barnes, N., Gavin, A.L., Tan, P.S., Mottram, P., Koentgen, F., Hogarth, P.M., FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16 (2002), 379–389.
4. Basso, K., Klein, U., Niu, H., Stolovitzky, G.A., Tu, Y., Califano, A., Cattoretti, G., Dalla-Favera, R., Tracking CD40 signaling during germinal center development. Blood 104 (2004), 4088–4096.
5. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M.S., Nussenzweig, M.C., Ravetch, J.V., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
6. Bruhns, P., Iannascoli, B., England, P., Mancardi, D.A., Fernandez, N., Jorieux, S., Daëron, M., Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
7. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S.M., Ettenberg, S., Knee, D.A., Wilson, N.S., Dranoff, G., Brogdon, J.L., Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210 (2013), 1685–1693.
8. Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N.S., Brogdon, J.L., OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol. Cell Biol. 92 (2014), 475–480.
9. Chowdhury, F., Johnson, P.W., Glennie, M.J., Williams, A.P., Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol. Res. 2 (2014), 229–240.
10. Chu, S.Y., Vostiar, I., Karki, S., Moore, G.L., Lazar, G.A., Pong, E., Joyce, P.F., Szymkowski, D.E., Desjarlais, J.R., Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol. Immunol. 45 (2008), 3926–3933.
11. Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A.J., Ravetch, J.V., FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28 (2015), 285–295.
12. DiLillo, D.J., Ravetch, J.V., Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161 (2015), 1035–1045.
13. Furman, R.R., Forero-Torres, A., Shustov, A., Drachman, J.G., A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51 (2010), 228–235.
14. Inwald, D.P., McDowall, A., Peters, M.J., Callard, R.E., Klein, N.J., CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92 (2003), 1041–1048.
15. Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034.
16. Li, F., Ravetch, J.V., A general requirement for FcgammaRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 11 (2012), 3343–3344.
17. Li, F., Ravetch, J.V., Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc. Natl. Acad. Sci. USA 110 (2013), 19501–19506.
18. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7 (2007), 95–106.
19. Meyer, T., Robles-Carrillo, L., Robson, T., Langer, F., Desai, H., Davila, M., Amaya, M., Francis, J.L., Amirkhosravi, A., Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J. Thromb. Haemost. 7 (2009), 171–181.
20. Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., Hattori, K., Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). Protein Eng. Des. Sel. 26 (2013), 589–598.
21. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
22. Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
23. Nimmerjahn, F., Bruhns, P., Horiuchi, K., Ravetch, J.V., FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005), 41–51.
24. Osoegawa, K., Mammoser, A.G., Wu, C., Frengen, E., Zeng, C., Catanese, J.J., de Jong, P.J., A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res. 11 (2001), 483–496.
25. Pincetic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebiger, B.M., Ravetch, J.V., Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
26. Ravetch, J.V., Nimmerjahn, F., Fc receptors and their role in immune regulation and inflammation. Paul, W.E., (eds.) Fundamental Immunology, Sixth Edition, 2008, Wolters Kluwer, Philadelphia, 684–705.
27. Richman, L.P., Vonderheide, R.H., Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2 (2014), 19–26.
28. Robles-Carrillo, L., Meyer, T., Hatfield, M., Desai, H., Davila, M., Langer, F., Amaya, M., Garber, E., Francis, J.L., Hsu, Y.M., Amirkhosravi, A., Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185 (2010), 1577–1583.
29. Ruter, J., Antonia, S.J., Burris, H.A., Huhn, R.D., Vonderheide, R.H., Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 10 (2010), 983–993.
30. Schwab, I., Lux, A., Nimmerjahn, F., Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice. Cell Rep. 13 (2015), 610–620.
31. Selby, M.J., Engelhardt, J.J., Quigley, M., Henning, K.A., Chen, T., Srinivasan, M., Korman, A.J., Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1 (2013), 32–42.
32. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
33. Smith, P., DiLillo, D.J., Bournazos, S., Li, F., Ravetch, J.V., Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109 (2012), 6181–6186.
34. Stylianos, B.D.D., Ravetch, J.V., Humanized mice to study FcγR function. Daeron, M., Nimmerjahn, F., (eds.) Fc Receptors, 2014, Springer International Publishing, Switzerland, 237–248.
35. van Sorge, N.M., van der Pol, W.L., van de Winkel, J.G., FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61 (2003), 189–202.
36. Vonderheide, R.H., Glennie, M.J., Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19 (2013), 1035–1043.
37. Vonderheide, R.H., Flaherty, K.T., Khalil, M., Stumacher, M.S., Bajor, D.L., Hutnick, N.A., Sullivan, P., Mahany, J.J., Gallagher, M., Kramer, A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25 (2007), 876–883.
38. Vonderheide, R.H., Burg, J.M., Mick, R., Trosko, J.A., Li, D., Shaik, M.N., Tolcher, A.W., Hamid, O., Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology, 2, 2013, e23033.
39. White, A.L., Chan, H.T., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., Dixon, S.V., Ajona, D., Verbeek, J.S., Al-Shamkhani, A., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763.
40. White, A.L., Chan, H.T., French, R.R., Willoughby, J., Mockridge, C.I., Roghanian, A., Penfold, C.A., Booth, S.G., Dodhy, A., Polak, M.E., et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27 (2015), 138–148.